Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Результаты клинического исследования PLATO и место тикагрелора в лечении острого коронарного синдрома
Результаты клинического исследования PLATO и место тикагрелора в лечении острого коронарного синдрома
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье приводится анализ результатов крупного международного рандомизированного клинического исследования PLATO, в котором изучался новый антиагрегант тикагрелор в сравнении с клопидогрелом в дополнение к ацетилсалициловой кислоте у пациентов с острым коронарным синдромом (ОКС). Материал содержит описание дизайна исследования, основных результатов, касающихся эффективности и безопасности тикагрелора. Кроме того, в материале представлены те части современных клинических руководств, в которых описывается место тикагрелора в лечении ОКС и которые были изменены по результатам исследования PLATO.
Ключевые слова: острый коронарный синдром, тикагрелор, клопидогрел, PLATO.
Key words: acute coronary syndrome, ticagrelor, clopidogrel, PLATO.
Ключевые слова: острый коронарный синдром, тикагрелор, клопидогрел, PLATO.
________________________________________________
Key words: acute coronary syndrome, ticagrelor, clopidogrel, PLATO.
Полный текст
Список литературы
1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365–72.
2. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–47.
3. Gubler PA, Bliden KP, Butler K et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. The ONSET/OFFSET Study. Circulation 2009; 120: 2577–85.
4. Wallentin L, Backer RC, Budaj A et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
5. James SK, Roe MT, Cannon CP et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial. BMJ 2011; 342: d3527.
6. Lindholm D, Varenhorst C, Cannon CP et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. doi:10.1093/eurheartj/ehu16.
7. Steg PG, James S, Harrington RA et al. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation 2010; 122: 2131–41.
8. Husted S, James S, Becker RC et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet ingibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5 (5): 680–8.
9. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus Clopidogrel in patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.
10. James SK, Storey RF, Khurmi NS et al. Ticagrelor versus Clopiogrel in patients with acute coronary syndromes and history of stroke or transient ischemic attack. Circulation 2012; 125 (23): 2914–21.
11. James S, Budaj A, Aylward P et al. Ticagrelor versus Clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trials. Circulation 2010; 122: 1056–67.
12. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rahabil 2007; 14: 312–8.
13. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J. doi: 10.1093/eurheartj/ehr236.
14. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J. doi:10.1093/eurheartj/ehs215;
15. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes http://content.onlinejacc.org/ on 10/12/2014.
2. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–47.
3. Gubler PA, Bliden KP, Butler K et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. The ONSET/OFFSET Study. Circulation 2009; 120: 2577–85.
4. Wallentin L, Backer RC, Budaj A et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
5. James SK, Roe MT, Cannon CP et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial. BMJ 2011; 342: d3527.
6. Lindholm D, Varenhorst C, Cannon CP et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. doi:10.1093/eurheartj/ehu16.
7. Steg PG, James S, Harrington RA et al. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation 2010; 122: 2131–41.
8. Husted S, James S, Becker RC et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet ingibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5 (5): 680–8.
9. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus Clopidogrel in patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.
10. James SK, Storey RF, Khurmi NS et al. Ticagrelor versus Clopiogrel in patients with acute coronary syndromes and history of stroke or transient ischemic attack. Circulation 2012; 125 (23): 2914–21.
11. James S, Budaj A, Aylward P et al. Ticagrelor versus Clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trials. Circulation 2010; 122: 1056–67.
12. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rahabil 2007; 14: 312–8.
13. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J. doi: 10.1093/eurheartj/ehr236.
14. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J. doi:10.1093/eurheartj/ehs215;
15. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes http://content.onlinejacc.org/ on 10/12/2014.
2. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–47.
3. Gubler PA, Bliden KP, Butler K et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. The ONSET/OFFSET Study. Circulation 2009; 120: 2577–85.
4. Wallentin L, Backer RC, Budaj A et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
5. James SK, Roe MT, Cannon CP et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial. BMJ 2011; 342: d3527.
6. Lindholm D, Varenhorst C, Cannon CP et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. doi:10.1093/eurheartj/ehu16.
7. Steg PG, James S, Harrington RA et al. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation 2010; 122: 2131–41.
8. Husted S, James S, Becker RC et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet ingibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5 (5): 680–8.
9. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus Clopidogrel in patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.
10. James SK, Storey RF, Khurmi NS et al. Ticagrelor versus Clopiogrel in patients with acute coronary syndromes and history of stroke or transient ischemic attack. Circulation 2012; 125 (23): 2914–21.
11. James S, Budaj A, Aylward P et al. Ticagrelor versus Clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trials. Circulation 2010; 122: 1056–67.
12. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rahabil 2007; 14: 312–8.
13. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J. doi: 10.1093/eurheartj/ehr236.
14. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J. doi:10.1093/eurheartj/ehs215;
15. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes http://content.onlinejacc.org/ on 10/12/2014.
________________________________________________
2. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–47.
3. Gubler PA, Bliden KP, Butler K et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. The ONSET/OFFSET Study. Circulation 2009; 120: 2577–85.
4. Wallentin L, Backer RC, Budaj A et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
5. James SK, Roe MT, Cannon CP et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial. BMJ 2011; 342: d3527.
6. Lindholm D, Varenhorst C, Cannon CP et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. doi:10.1093/eurheartj/ehu16.
7. Steg PG, James S, Harrington RA et al. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation 2010; 122: 2131–41.
8. Husted S, James S, Becker RC et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet ingibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5 (5): 680–8.
9. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus Clopidogrel in patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.
10. James SK, Storey RF, Khurmi NS et al. Ticagrelor versus Clopiogrel in patients with acute coronary syndromes and history of stroke or transient ischemic attack. Circulation 2012; 125 (23): 2914–21.
11. James S, Budaj A, Aylward P et al. Ticagrelor versus Clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trials. Circulation 2010; 122: 1056–67.
12. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rahabil 2007; 14: 312–8.
13. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J. doi: 10.1093/eurheartj/ehr236.
14. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J. doi:10.1093/eurheartj/ehs215;
15. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes http://content.onlinejacc.org/ on 10/12/2014.
Авторы
А.Д.Эрлих
ГКБ №29 им. Н.Э.Баумана ДЗ г. Москвы. 111020, Москва, Россия, Госпитальная пл., д. 2;
ФГБУН НИИ физико-химической медицины ФМБА России. 119435, Россия, Москва, ул. Малая Пироговская, д. 1а
alexeyerlikh@gmail.com
29 Bauman City Clinical Hospital. 111020, Russian Federation, Moscow, Gospital'naya pl., d. 2;
Institute of Physico-Chemical Medicine of Russia. 119435, Russian Federation, Moscow, ul. Malaya Pirogovskaya, d. 1a
alexeyerlikh@gmail.com
ГКБ №29 им. Н.Э.Баумана ДЗ г. Москвы. 111020, Москва, Россия, Госпитальная пл., д. 2;
ФГБУН НИИ физико-химической медицины ФМБА России. 119435, Россия, Москва, ул. Малая Пироговская, д. 1а
alexeyerlikh@gmail.com
________________________________________________
29 Bauman City Clinical Hospital. 111020, Russian Federation, Moscow, Gospital'naya pl., d. 2;
Institute of Physico-Chemical Medicine of Russia. 119435, Russian Federation, Moscow, ul. Malaya Pirogovskaya, d. 1a
alexeyerlikh@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.